Share-based Payment Arrangement, Expense of ADIAL PHARMACEUTICALS, INC. from 30 Sep 2017 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
ADIAL PHARMACEUTICALS, INC. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 30 Sep 2017 to 30 Sep 2025.
  • ADIAL PHARMACEUTICALS, INC. Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $147,334, a 22% decline year-over-year.
  • ADIAL PHARMACEUTICALS, INC. Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2025 was $688,366, a 23% decline year-over-year.
  • ADIAL PHARMACEUTICALS, INC. annual Share-based Payment Arrangement, Expense for 2024 was $796,831, a 54% decline from 2023.
  • ADIAL PHARMACEUTICALS, INC. annual Share-based Payment Arrangement, Expense for 2023 was $1,746,378, a 48% decline from 2022.
  • ADIAL PHARMACEUTICALS, INC. annual Share-based Payment Arrangement, Expense for 2022 was $3,374,493, a 20% decline from 2021.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

ADIAL PHARMACEUTICALS, INC. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $688,366 $147,334 -$40,927 -22% 01 Jul 2025 30 Sep 2025 10-Q 13 Nov 2025 2025 Q3
Q2 2025 $729,293 $124,099 -$78,279 -39% 01 Apr 2025 30 Jun 2025 10-Q 13 Aug 2025 2025 Q2
Q1 2025 $807,572 $236,731 +$10,741 +4.8% 01 Jan 2025 31 Mar 2025 10-Q 14 May 2025 2025 Q1
Q4 2024 $796,831 $180,202 -$100,645 -36% 01 Oct 2024 31 Dec 2024 10-K 04 Mar 2025 2024 FY
Q3 2024 $897,476 $188,261 -$80,113 -30% 01 Jul 2024 30 Sep 2024 10-Q 13 Nov 2025 2025 Q3
Q2 2024 $977,589 $202,378 -$535,202 -73% 01 Apr 2024 30 Jun 2024 10-Q 13 Aug 2025 2025 Q2
Q1 2024 $1,512,791 $225,990 -$233,587 -51% 01 Jan 2024 31 Mar 2024 10-Q 14 May 2025 2025 Q1
Q4 2023 $1,746,378 $280,847 -$453,297 -62% 01 Oct 2023 31 Dec 2023 10-K 04 Mar 2025 2024 FY
Q3 2023 $2,199,675 $268,374 -$288,641 -52% 01 Jul 2023 30 Sep 2023 10-Q 13 Nov 2024 2024 Q3
Q2 2023 $2,488,316 $737,580 -$362,142 -33% 01 Apr 2023 30 Jun 2023 10-Q 13 Aug 2024 2024 Q2
Q1 2023 $2,850,458 $459,577 -$524,035 -53% 01 Jan 2023 31 Mar 2023 10-Q 12 May 2023 2023 Q1
Q4 2022 $3,374,493 $734,144 01 Oct 2022 31 Dec 2022 10-K 01 Apr 2024 2023 FY
Q3 2022 $557,015 -$631,862 -53% 01 Jul 2022 30 Sep 2022 10-Q 14 Nov 2023 2023 Q3
Q2 2022 $1,099,722 01 Apr 2022 30 Jun 2022 10-Q/A 30 Oct 2023 2023 Q2
Q1 2022 $983,612 -$1,229,797 -56% 01 Jan 2022 31 Mar 2022 10-Q 12 May 2023 2023 Q1
Q3 2021 $1,188,877 01 Jul 2021 30 Sep 2021 10-Q 14 Nov 2022 2022 Q3
Q1 2021 $2,213,409 +$970,409 +78% 01 Jan 2021 31 Mar 2021 10-Q 17 May 2021 2021 Q1
Q1 2020 $1,243,000 01 Jan 2020 31 Mar 2020 10-Q 14 May 2020 2020 Q1
Q1 2020 $117,001 17 Feb 2020 03 Mar 2020 10-Q 14 May 2020 2020 Q1
Q3 2018 $31,473 -$33,656 -52% 01 Jul 2018 30 Sep 2018 10-Q 14 Nov 2018 2018 Q3
Q3 2017 $65,129 01 Jul 2017 30 Sep 2017 10-Q 14 Nov 2018 2018 Q3

ADIAL PHARMACEUTICALS, INC. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $796,831 -$949,547 -54% 01 Jan 2024 31 Dec 2024 10-K 04 Mar 2025 2024 FY
2023 $1,746,378 -$1,628,115 -48% 01 Jan 2023 31 Dec 2023 10-K 04 Mar 2025 2024 FY
2022 $3,374,493 -$865,924 -20% 01 Jan 2022 31 Dec 2022 10-K 01 Apr 2024 2023 FY
2021 $4,240,417 +$2,819,912 +199% 01 Jan 2021 31 Dec 2021 10-K 30 Mar 2023 2022 FY
2020 $1,420,505 01 Jan 2020 31 Dec 2020 10-K 22 Mar 2021 2020 FY
2018 $251,903 +$116,012 +85% 01 Jan 2018 31 Dec 2018 10-K 19 Feb 2019 2018 FY
2017 $135,891 01 Jan 2017 31 Dec 2017 10-K 19 Feb 2019 2018 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.